Cardiovascular diseases in diabetic patients

Cover Page

Cite item

Full Text

Abstract

The review pays attention to a considerable rise in the incidence of diabetes mellitus (DM) and to its association with cardiovascular diseases (CVD) and events. It is noted that these events may be present much earlier than DM is diagnosed. The paper also discusses in detail a role of hyperglycemia, postprandial one in particular, hyperinsulinemia, insulin resistance, endothelial dysfunction, impaired blood rheological properties, lipid metabolic disturbances, and genetic and traditional risk factors in the development of atherosclerosis, coronary heart disease, chronic heart failure, cerebrovascular diseases, and lower extremity ischemia in DM.

About the authors

I. Y Yarek-Martynova

Endocrinology Research Center, Russian Academy of Medical Sciences, Moscow

ст. науч. сотр., Институт диабета

M. V Shestakova

Endocrinology Research Center, Russian Academy of Medical Sciences, Moscow

д-р мед. наук, проф. директор Института диабета

References

  1. King H, Aubert R.E., Herman W.H. Global burden of diabetes, 1995–2025: prevalence, numerical estimates and projections. Diabet Care 1998; 21: 1414–31.
  2. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabet Care 2004; 27: 1047–53.
  3. Дедов И.И., Шестакова М.В. Сахарный диабет – глобальная медико - социальная проблема современности. Медицина – целевые проекты. 2007; 1: 26–9.
  4. http://www.diabetesatlas.org/content/diabetes - and - impaired - glucose - tolerance. Assesed December 15.2009
  5. Harris M.I. Undiagnosed NIDDM: clinical and public health issues. Diabet Care 1993; 16: 642–52.
  6. Hu F.B. Stampfer M.J., Haffner S.M. et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabet Care 2002; 25: 1880–90
  7. Шестакова М.В., Бутрова С.А., Сухарева О.Ю. Метаболический синдром как предвестник развития сахарного диабета 2-го типа и сердечно - сосудистых заболеваний. Тер. арх. 2007; 10: 5–8.
  8. Bartnik M, Ryden L, Ferrari R et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 2004; 25: 1880–90.
  9. Kowalska I, Prokop J, Bachorzewska-Gajewska H et al. Disturbances of glucose metabolism in men referred for coronary angiography. Diabet Care 2001; 24: 897–901.
  10. Gu K, Cowie C.C., Harris N. Diabetes and decline in Heart Disease Mortality in US. JAMA 1999; 281: 1291–7.
  11. Quyyumi A.A. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998; 105: 32S–9.
  12. Arbogast B.W., Lee G.M., Raymond T.L. In vitro injury of porcine aortic endothelial cells by very low density lipoproteins from diabetic rat serum. Diabetes 1982; 31: 593–9.
  13. Avogaro A, Calo L, Piaruli F et al. Effect of acute ketosis on the endothelial function of type 1 diabetic patients: the rote of nitric oxide. Diabet 1999; 48: 391–7.
  14. Cipolla M.J. Elevated glucose potentiates contraction of isolated rat resistance arteries and augments protein kinase C-induced intracellular calcium release. Metabolism 1999; 48: 1015–22.
  15. Dosquet C, Wautier M.F., Guillausseau P.J., Wautier J.L. Monokines and endothelial cell proliferation in patients with diabetes mellitus. Diabet Metab 1994; 20: 37–42.
  16. Elhadd T.A., Khan F, Kirk G et al. Influence of puberty on endothelial dysfunction and oxidative stress in young patients with type 1 diabetes. Diabet Care 1998; 21: 1990–6.
  17. Makimattila S, Virkamaki A, Groop PH et al. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin - dependent diabetes mellitus. Circulation 1996; 94: 1276–82.
  18. Викулова О.К., Ярек-Мартынова И.Р., Трубицина Н.П., Шестакова М.В. Показатели вазомоторной функции эндотелия и эластичности артериальной стенки при терапии ингибитором ангиотензинпревращающего фермента рамиприлом у больных сахарным диабетом 2-го типа. Кардиология. 2008; 11: 47–52.
  19. Чазова Т.Е., Катхурия Ю.Б. Сахарный диабет и сердечно - сосудистые заболевания: факторы риска, клинические особенности, диагностика. Мед. помощь. 2001; 5: 28–32.
  20. Арутюнов Г.П. Сахарный диабет и атеросклероз: Какова оптимальная стратегия сдерживания атеросклеротического процесса? Сердце. 2004; 3 (1): 36–8.
  21. Morrish N.J., Wang S.L., Stevens L.K. et al. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001; 44 (Suppl. 2): S14–21.
  22. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, patophysiology and management. JAMA 2002; 287: 2570–81.
  23. Meigs J.B. Epidemilogy of cardiovascular complications in type2 diabetes mellitus. Acta Diabetol 2003; 40 (Suppl. 2): S358–61.
  24. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease. The Framingham Study. JAMA 1979; 241: 2035–8.
  25. Шестакова М.В., Мухин Н.А., Дедов И.И. и др. Восстановление резерва фильтрационной функции почек у больных сахарным диабетом при лечении каптоприлом. Тер. арх. 1991; 6: 50–5.
  26. Jensen T, Borch-Johnsen K, Kofoed-Enevoldsen A, Deckert T. Coronary heart disease in young type 1 (insulin - dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987; 30 (3): 144–8.
  27. Tuomilehto J, Borch-Johnsen K, Molarius A et al. Incidence of cardiovascular disease in Type 1 (insulin - dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 1998; 41 (7): 784–90.
  28. Шестакова М.В., Ярек-Мартынова И.Р., Иванишина Н.С. и др. Кардиоренальный синдром при сахарном диабете 1 типа: роль дисфункции эндотелия. Кардиология. 2005; 6: 35–41.
  29. Goya W.S. Serum uric acid is not an independent risk factor for coronary heart disease. Curr Hypertens Reports 2001; 3: 190–6.
  30. Saito I, Folsom A.R., Brancati F.L. et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerotoc Risk in Communities (ARIC) study. Ann Intern Med 2000; 133: 81–91.
  31. Poulsen P.L., Hansen K.W., Mogensen C.E. Ambulatory blood pressure in the transition from normo - to microalbuminuria. Diabetes 1994; 43: 1248–53.
  32. Бейтуганов А.А., Рылова А.К. Встречаемости СД 2 типа у больных ХСН. Сердеч. недостаточ. 2005; 6: 114–6.
  33. Nichols G.A., Hillier T.A., Erbey J.R., Brown J.B. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factor. Diabet Сare 2001; 24: 1614–9.
  34. Нарусов О.Ю., Лапина Ю.В., Мареев В.Ю. и др. Влияние тяжести хронической сердечной недостаточности на течение сопутствующего сахарного диабета 2-го типа. Тер. арх. 2009; 9: 52–7.
  35. Rosei-Agabiti E, Muiesan M.L. Hypertensive left ventricular hypertrophy: pathophysiological and clinical issues. Blood Pressure 2001; 10 (5–6): 288–8.
  36. Castelli W. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984; 76 (Suppl. 2 A): 4–12.
  37. Sato A, Tarnow L, Parving H.H. Prevalence of left ventricular hypertrophy in type 1 diabetic patients with diabetic nephropathy. Diabetologia 1999; 42: 76–80.
  38. Salmasi A.M., Jepson E, Grenfell A et ak. The degree of albuminuria is related to left ventricular hypertrophy in hypertensive diabetics and is associated with abnormal left ventricular filling: a pilot study. Angiology 2003; 54 (6): 671–8.
  39. Palmieri V, Tracy R.P., Roman M.J. et al. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes. Diabetes Care 2003; 26: 2764–9.
  40. Saito I, Folsom A.R., Brancati F.L. et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerotoc Risk in Communities (ARIC) study. Ann Intern Med 2000; 133: –91.
  41. Stamler J, Vaccaro O, Neaton J.D. et al. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in The Multiple Risk Factor Intervention Trial. Diabet Care 1993; 16: 434–44.
  42. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population perspective. Diabetologia 1995; 38: 1061–8.
  43. Kagansky N, Levy S The Role of Hyperglycemia in Acute Stroke. Arch Neurol 2001; 58: 1209–12.
  44. Chamorro A, Vila N, Ascaso C et al. Early Prediction of Stroke Severity. Stroke 1995; 26: 573–6.
  45. Alvarez-Sabín J, Molina C.A., Montaner J et al. Effects of Admission Hyperglycemia on Stroke Outcome in Reperfused Tissue Plasminogen Activator-Treated Patients. Stroke 2003; 34: 1235–40.
  46. Grau A.J., Weimar C, Buggle F et al. Risk Factors, Outcome, and Treatment in Subtypes of Ischemic Stroke: The German Stroke Data Bank. Stroke 2001; 32: 2559–66.
  47. Karapanayiotides T, Piechowski-Jozwiak B, van Melle G et al. Stroke patterns, etiology, and prognosis in patients with diabetes mellitus. Neurology 2004; 11 (62): 1558–62.
  48. Leibson C.L., Rocca W.A., Hanson V.A. Risk of dementia among persons with diabetes mellitus: a population - based cohort study. Am J Epidemiol 1997; 145: 301–8.
  49. Чугунова Л.А., Тарасов Е.В., Шестакова М.В. Инсульт и сахарный диабет 2-го типа. Возможности профилактики. Тер. арх. 2006; 10: 21–6.
  50. Галстян Г.Р. Поражения нижних конечностей у больных сахарным диабетом. Cons. Med. 2006; 9.

Copyright (c) 2010 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies